Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec:156:261-267.
doi: 10.1016/j.jpsychires.2022.09.051. Epub 2022 Oct 13.

Can machine learning identify childhood characteristics that predict future development of bipolar disorder a decade later?

Affiliations

Can machine learning identify childhood characteristics that predict future development of bipolar disorder a decade later?

Mai Uchida et al. J Psychiatr Res. 2022 Dec.

Abstract

Early identification of bipolar disorder may provide appropriate support and treatment, however there is no current evidence for statistically predicting whether a child will develop bipolar disorder. Machine learning methods offer an opportunity for developing empirically-based predictors of bipolar disorder. This study examined whether bipolar disorder can be predicted using clinical data and machine learning algorithms. 492 children, ages 6-18 at baseline, were recruited from longitudinal case-control family studies. Participants were assessed at baseline, then followed-up after 10 years. In addition to sociodemographic data, children were assessed with psychometric scales, structured diagnostic interviews, and cognitive and social functioning assessments. Using the Balanced Random Forest algorithm, we examined whether the diagnostic outcome of full or subsyndromal bipolar disorder could be predicted from baseline data. 45 children (10%) developed bipolar disorder at follow-up. The model predicted subsequent bipolar disorder with 75% sensitivity, 76% specificity, and an Area Under the Receiver Operating Characteristics of 75%. Predictors best differentiating between children who did or did not develop bipolar disorder were the Child Behavioral Checklist Externalizing and Internalizing behaviors, the Child Behavioral Checklist Total t-score, problematic school functions indexed through the Child Behavioral Checklist School Competence scale, and the Child Behavioral Checklist Anxiety/Depression and Aggression scales. Our study provides the first quantitative model to predict bipolar disorder. Longitudinal prediction may help clinicians assess children with emergent psychopathology for future risk of bipolar disorder, an area of clinical and scientific importance. Machine learning algorithms could be implemented to alert clinicians to risk for bipolar disorder.

Keywords: Bipolar disorder; Machine learning; Mood disorders; Pediatric bipolar disorder.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Mai Uchida is partially supported by a K award, grant number 1K23MH122667-01. Dr. Uchida also provided a one-time consultation to the Moderna scientific advisory board. Allison Green received funding from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under award number T32HD007475. In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Akili, Genomind, Ironshore, KemPharm/Corium, Noven, Ondosis, Otsuka, Rhodes, Supernus, Takeda, Tris and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Alcobra, Arbor, Aveksham, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, Lundbeck/Takeda, McNeil, NeuroLifeSciences, Neurovance, Novartis, Pfizer, Shire, and Sunovion. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child's Mental Health; Oxford University Press: Schizophrenia: The Facts; and Elsevier: ADHD: Non-Pharmacologic Interventions. He is also Program Director of www.adhdinadults.com. Dr. Faraone is supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 965381; NIMH grants U01AR076092-01A1, 1R21MH1264940, R01MH116037; Oregon Health and Science University, Otsuka Pharmaceuticals, Noven Pharmaceuticals Incorporated, and Supernus Pharmaceutical Company. Dr. Joseph Biederman is currently receiving research support from the following sources: AACAP, Feinstein Institute for Medical Research, Genentech, Headspace Inc., NIDA, Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., Tris, and NIH. Dr. Biederman and his program have received royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire/Takeda, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. Through Partners Healthcare Innovation, Dr. Biederman has a partnership with MEMOTEXT to commercialize a digital health intervention to improve adherence in ADHD. Through MGH corporate licensing, Dr. Biederman has a US Patent (#14/027,676) for a non-stimulant treatment for ADHD, a US Patent (#10,245,271 B2) on a treatment of impaired cognitive flexibility, and a patent pending (#61/233,686) on a method to prevent stimulant abuse. In 2022: Dr. Biederman received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. In 2021: Dr. Biederman received an honorarium for a scientific presentation from Multi-Health Systems, and a one-time consultation for Cowen Healthcare Investments. He received honoraria from AACAP, the American Psychiatric Nurses Association, BIAL - Portela & C(a). S.A. (Portugal), Medscape Education, and MGH Psychiatry Academy for tuition-funded CME courses. In 2020: Dr. Biederman received an honorarium for a scientific presentation from Tris and from the Institute of Integrated Sciences – INI (Brazil), and research support from the Food & Drug Administration. He received honoraria from Medlearning Inc, NYU, and MGH Psychiatry Academy for tuition-funded CME courses. In 2019, Dr. Biederman was a consultant for Akili, Avekshan, Jazz Pharma, and Shire/Takeda. He received research support from Lundbeck AS and Neurocentria Inc. Through MGH CTNI, he participated in a scientific advisory board for Supernus. He received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. Dr. Qasim Bukhari, Ms. Maura DiSalvo, Dr. Guilla Serra, Ms. Chloe Hutt Vater, Dr. Satrajit Ghosh, and Dr. John Gabrieli do not have any financial relationships to disclose.

Figures

Fig. 1.
Fig. 1.
Precision-Recall curve of bipolar disorder prediction for several cross-validation iterations. The figure shows the median precision-recall of all iterations of the cross-validation.
Fig. 2.
Fig. 2.
ROC-AUC curve of bipolar disorder prediction for several cross-validation iterations. The figure shows the median ROC-AUC of all iterations of the cross-validation.

References

    1. Achenbach TM, 1991. Manual for the Child Behavior Checklist/4-18 and the 1991 Profile. University of Vermont, Department of Psychiatry, Burlington, VT.
    1. Althoff RR, Rettew DC, Ayer LA, Hudziak JJ, 2010. Cross-informant agreement of the dysregulation profile of the child behavior checklist. Psychiatr. Res 178 (3), 550–555. - PMC - PubMed
    1. Arbabshirani MR, Plis S, Sui J, Calhoun VD, 2017. Single subject prediction of brain disorders in neuroimaging: promises and pitfalls. Neuroimage 145 (Pt B), 137–165. - PMC - PubMed
    1. Biederman J, Faraone SV, Chu MP, Wozniak J, 1999. Further evidence of a bidirectional overlap between juvenile mania and conduct disorder in children. J. Am. Acad. Child Adolesc. Psychiatry 38 (4), 468–476. - PubMed
    1. Biederman J, Faraone SV, Petty C, Martelon M, Woodworth KY, Wozniak J, 2013. Further evidence that pediatric-onset bipolar disorder comorbid with ADHD represents a distinct subtype: results from a large controlled family study. J. Psychiatr. Res 47 (1), 15–22. - PMC - PubMed

Publication types